ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings
  • Abstract Number: 0154 • ACR Convergence 2025

    Incidence and Prevalence of Connective Tissue Diseases with Interstitial Lung Disease (CTD-ILD) in the United States

    Diana Martins1, George Mu2, Elaine Irving3, Roger A. Levy4, Nisha Bhatt5 and Keele E. Wurst6, 1GSK, Epidemiology, Toronto, ON, Canada, 2GSK, Statistics, Collegeville, PA, 3GSK, Clinical, Stevenage, United Kingdom, 4GSK, Specialty Care, Global Medical Affairs, Collegeville, PA, 5GSK, Global Medical Affairs, Collegeville, PA, 6GSK, Immunology and Emerging Epidemiology, Durham, NC

    Background/Purpose: Despite the high disease burden and reduced quality of life for patients with CTD-ILD, data on its incidence and prevalence – particularly by CTD…
  • Abstract Number: 0215 • ACR Convergence 2025

    Impact of Global Review on Comorbidity Management in Inflammatory Arthritis Patients

    Alexandra Kobza1, Camille Bourgeois2, Olivier Fogel3, Maxime Dougados4 and Anna Molto5, 1University of Calgary, North Vancouver, BC, Canada, 2Hospital general universitario Gregorio Marañon, Madrid, Madrid, Spain, 3AP-HP, Paris, France, 4Department of Medicine, Hopital Cochin, Universite de Paris, Paris, France, 5Assistance Publique Hôpitauxde Paris, Paris, France

    Background/Purpose: Patients with inflammatory arthritis (IA), including rheumatoid arthritis (RA) and spondyloarthritis (SpA), face elevated risk for comorbidities that complicate disease management. Although rheumatology societies…
  • Abstract Number: 0106 • ACR Convergence 2025

    Investigation of DNA Methylation Inhibition in a Mouse Model of Ankylosing Spondylitis

    Goh Murayama1, Kurisu Tada2, Naoto Tamura3, Eri Hayashi1, Taiga Kuga4, Ken Yamaji5 and HOSHIKO FURUSAWA6, 1Department of Internal Medicine and Rheumatology, Juntendo University Graduate School of Medicine, Tokyo, Japan, 2Department of Internal Medicine and Rheumatology, Juntendo University Graduate School of Medicine, Tokyo, 3Juntendo University School of Medicine, Tokyo, Japan, 4Juntendo University, Tokyo, Japan, 5Juntendo University, Department of Internal Medicine and Rheumatology, Tokyo, Japan, 6juntendo, tokyo, Japan

    Background/Purpose: Ankylosing spondylitis (AS) is a chronic inflammatory disease characterized by enthesitis in axial joints, bone erosion near the entheses, and subsequent irreversible ankylosis due…
  • Abstract Number: 0049 • ACR Convergence 2025

    Enhanced Src Homology Region 2 Domain-containing Phosphatase 1 Activity Ameliorates Murine Inflammatory Arthritis Through the Innate Immune System

    Jun Li, Katalin Mikecz and Adrienn Markovics, Rush University Medical Center, Chicago

    Background/Purpose: Src homology region 2 domain-containing phosphatase 1 (SHP-1) is a cytoplasmic protein tyrosine phosphatase expressed in hematopoietic cells (PMID9069265). SHP-1 is a key negative…
  • Abstract Number: 0027 • ACR Convergence 2025

    Consistent Method to Generate Hyaline Cartilage from Human Induced Pluripotent Stem Cell-Derived Multi-Tissue Organoids

    Huzefa Husain1, Manci Li2, Juan Abrahante3, Natalia Mancipe3, Amanda Vegoe4, Yi Wen Chai5, Beth Lindborg6, Marc Tompkins7, Brenda Ogle8, Peter Larsen9, Timothy O'Brien10 and Ferenc Tóth11, 1Department of Biomedical Engineering, University of Minnesota, Minneapolis, 2Department of Electrical and Computer Engineering, Minnesota Center for Prion Research and Outreach, University of Minnesota, Minneapolis, 3Minnesota Supercomputing Institute, University of Minnesota, Minneapolis, 4Department of Veterinary Population Medicine and Stem Cell Institute, University of Minnesota, Sarcio, Inc, St. Paul, 5Stem Cell Institute, University of Minnesota, Minneapolis, 6Sarcio, Inc., St. Paul, 7Department of Orthopedic Surgery, University of Minnesota, Sarcio, Inc., Minneapolis, 8Department of Biomedical Engineering, Stem Cell Institute, University of Minnesota, Minneapolis, 9Department of Veterinary and Biomedical Sciences, Minnesota Center for Prion Research and Outreach, University of Minnesota, St. Paul, 10Department of Veterinary Population Medicine and Stem Cell Institute, University of Minnesota, Sarcio, Inc, Minneapolis, 11Department of Veterinary Clinical Sciences, University of Minnesota, St. Paul

    Background/Purpose: Existing methods to produce hyaline cartilage from human induced pluripotent stem cells (hiPSCs) face significant limitations, such as complex culture conditions, instability of the…
  • Abstract Number: 0229 • ACR Convergence 2025

    Leveraging the Electronic Medical Record to Improve the Rate of Discrete Data Collection in a Pediatric Rheumatology Clinic

    Lisa Buckley1 and Eli Lourie2, 1Monroe Carell Jr. Children's Hospital at Vanderbilt, Nashville, TN, 2Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA

    Background/Purpose: A systematic approach to clinical data collection is critical to enhancing patient outcomes, enabling research and quality improvement initiatives, and benchmarking performance. This quality…
  • Abstract Number: 0150 • ACR Convergence 2025

    Mortality in Anca-associated Vasculitis

    Fabricio Benavides Villanueva1, Vanesa Calvo-Río2, Diana Prieto-Peña3, Monica Renuncio-García4, Adrian Martin-Gutierrez5, Amparo Sanchez-Lopez6, Claudia Poo-fernandez7, Clara Escagedo-Cagigas8, maria Rodríguez-Vidriales8 and Ricardo Blanco2, 1Division of Rheumatology, Hospital Universitario Marques de Valdecilla, IDIVAL, Immunopathology Group,Santander, Spain, Santander, Spain, 2Rheumatology Division, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain, Santander, Cantabria, Spain, 3Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain., Santander, Spain, 4Division of Immunology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain., Santander, Cantabria, Spain, 5Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain., Renedo de Piélagos, Spain, 6Division of Dermatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain., Santander, Cantabria, Spain, 7Division of Pneumology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain., Santander, Cantabria, Spain, 8Division of Nephrology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain., Santander, Cantabria, Spain

    Background/Purpose: Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), include Granulomatosis with Polyangiitis (GPA), Microscopic Polyangiitis (MPA), and Eosinophilic Granulomatosis with Polyangiitis (EGPA). Mortality rates are scare,…
  • Abstract Number: 0204 • ACR Convergence 2025

    Immunogenicity and safety summary for the chikungunya virus-like particle vaccine development programme

    Lauren Tindale1, Jason Richardson1, Deborah Anderson1, Jason Mendy2, Sufia Muhammad2, Tobi Loreth1, Victoria Jenkins3, Krystal Valenzuela4, Benedetto Simone5, Patrick Ajiboye2 and Lisa Bedell4, 1Bavarian Nordic Canada Inc., Toronto, Canada, 2Bavarian Nordic, Inc., San Diego, 3Bavarian Nordic Belgium, Brussels, Belgium, 4Bavarian Nordic, Inc., Durham, 5Bavarian Nordic Berna GmbH, Thoerishaus, Switzerland

    Background/Purpose: Chikungunya virus (CHIKV) is a threat to public health and a risk for travellers to endemic countries. Typical acute symptoms include fever, arthralgia, myalgia,…
  • Abstract Number: 0213 • ACR Convergence 2025

    Development of a Predictive Tool for Obstetric Risk Stratification in Autoimmune Rheumatic Diseases: A Meta-Analysis-Based Model

    Noe Macias-Segura1, Rodolfo Martinez-Canales1, Braulio R. Avalos-Garcia2, Andres M. Ortiz-Rios2, Eva Abigaid Galindo-Calvillo2, Mario Cesar Salinas-Carmona1, Lorena Perez-Barbosa2, Dionicio A. Galarza-Delgado3 and Cassandra Michele Skinner-Taylor2, 1Immunology Service, Hospital Universitario Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, Monterrey, Nuevo Leon, Mexico, 2Rheumatology Service, Hospital Universitario Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, Monterrey, Nuevo Leon, Mexico, 3Rheumatology Service, Hospital Universitario Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, Monterrey, Mexico

    Background/Purpose: Autoimmune rheumatic diseases (ARDs) such as systemic lupus erythematosus (SLE), antiphospholipid syndrome (APS), rheumatoid arthritis (RA), and Sjögren's syndrome significantly increase the risk of…
  • Abstract Number: 0196 • ACR Convergence 2025

    Increasing Timely Rheumatology Evaluation for High Risk Lupus Patients

    Steven Taylor1 and Elena Weinstein2, 1University of Colorado, Denver, CO, 2University of Colorado, Englewood, CO

    Background/Purpose: The rheumatology workforce shortage presents many challenges to the delivery of rheumatology care. Improving timely access to rheumatology for patients with life or organ…
  • Abstract Number: 0014 • ACR Convergence 2025

    NKX019, an allogeneic off-the-shelf CD19 targeting CAR-NK cell therapy, induces deep CD19+ B cell depletion in hematological malignancy and models of autoimmune disease

    Mira Tohmé, Meriam Vejiga, Wendy Yu, Emily Kang, Katharine Yu, Jessica Sood, Ivan Chan, Kyle Hansen, David Shook and Phung Gip, Nkarta, South San Francisco, CA

    Background/Purpose: Autologous CAR T-cell therapies have remarkable clinical activity in autoimmune disease (AD) via B-cell targeting, with many patients achieving durable, drug-free remission. However, safety…
  • Abstract Number: 0218 • ACR Convergence 2025

    Creating an EHR Lupus Outreach Workbench to Address Care Gaps

    Ross Gilbert1, Starla Blanks2, Joy Buie3, Mary Cronin4, Jake Decker5, Laura Dickmann6, Cristina Drenkard7, Sancia Ferguson8, Shivani Garg9, David Gazeley5, Andrea Gilmore-Bykovskyi10, Gale Johnson11, Patti Katz12, Tristan Lazewski13, S. Sam Lim14, Jenna McGoldrick15, Katrina Phelps10, Edmond Ramly16, Rosalind Ramsey-Goldman17, Ann Rosenthal18, Dawn Thomas-Semanko19, Sarah Stoltz13, Patricia Tellez-giron20, Amannda Weber21, Andrea Wipperfurth13 and Christie Bartels10, 1Johns Hopkins University, Baltimore, MD, 2American College of Rheumatology, Atlanta, GA, 3Lupus Foundation of America, Washington, DC, 4retired, Fox Point, WI, 5Medical College of Wisconsin, Milwaukee, WI, 6Froedtert Health, Waukesha, WI, 7Rollins School of Public Health, Emory University, Atlanta, Georgia, USA, Acworth, GA, 8University of Wisconsin School of Medicine and Public Health, Madison, Madison, WI, 9University of Madison, School of Medicine and Public Health, Madison, WI, 10University of Wisconsin School of Medicine and Public Health, Madison, WI, 11Wisconsin Department of Health Services, Madison, WI, 12UCSF, San Rafael, CA, 13UW Health, Madison, WI, 14Emory University School of Medicine, Atlanta, GA, 15SSM Health, Madison, WI, 16Indiana University - Bloomington, Bloomington, IN, 17Northwestern University Feinberg School of Medicine, Chicago, IL, 18Department of Medicine, Division of Rheumatology, Medical College of Wisconsin, Wisconsin, 19WI Chapter - LFA, Milwaukee, WI, 20University of Wisconsin, School of Medicine and Public Health, Madison, Madison, WI, 21University of Wisconsin (UW), UW Health, Madison, WI

    Background/Purpose: Lupus affects up to 1.5 million people in the US with significant health disparities in care and outcomes that call for care delivery innovation.…
  • Abstract Number: 0119 • ACR Convergence 2025

    Thrombin Generation Assays Inform Hypercoagulability Mediated by Antiphospholipid Antibodies in Children with Systemic Lupus Erythematosus

    Elizabeth Sloan1, Blake Baay2, Lynnette Walters2, Paola Sparagana2, Kristina Ciaglia1, Simrat Morris1, Julie Fuller1, Lorien Nassi1, Tracey Wright1 and Ayesha Zia3, 1UT Southwestern, Children's Medical Center, and Scottish Rite for Children, Dallas, TX, 2Scottish Rite for Children, Dallas, TX, 3UT Southwestern and Children's Medical Center, Dallas, TX

    Background/Purpose: In pediatric systemic lupus erythematosus (SLE), antiphospholipid antibodies (aPL) are independent risk factors for thrombosis. However, data are limited on how aPL impact hypercoagulability.…
  • Abstract Number: 0214 • ACR Convergence 2025

    Systematic Comorbidity Screening in Inflammatory Arthritis: The Experience of a Tertiary-Care Centre

    Camille Bourgeois1, Alexandra Kobza2, Olivier Fogel3, Maxime Dougados4 and Anna Molto5, 1Hospital general universitario Gregorio Marañon, Madrid, Madrid, Spain, 2University of Calgary, North Vancouver, BC, Canada, 3AP-HP, Paris, France, 4Department of Medicine, Hopital Cochin, Universite de Paris, Paris, France, 5Assistance Publique Hôpitauxde Paris, Paris, France

    Background/Purpose: Patients with inflammatory arthritis (IA), including rheumatoid arthritis (RA) and spondyloarthritis (SpA), are at elevated risk for comorbidities, complicating disease management. Despite rheumatology societies…
  • Abstract Number: 0220 • ACR Convergence 2025

    National Implementation of a Medication Safety Dashboard to Improve HLA-B*58:01 Testing Among Allopurinol Users in the Veterans Health Administration

    Alissa Becerril1, Jing Li2, Cherish Wilson3, Gary Tarasovsky4, Abimbola Fadairo-Azinge5, Mary Whooley4 and gabriela Schmajuk6, 1UCSF, san francisco, CA, 2University of California, San Francisco, San Francisco, CA, 3UCSF / SFVA, San Francisco, CA, 4SFVA, San Francisco, 5UCSF, San Francisco, 6University of California, San Francisco, and San Francisco Veterans Affairs Medical Center, San Francisco, CA

    Background/Purpose: Allopurinol can cause life-threatening severe cutaneous adverse reactions, especially in patients who carry the HLA-B58:01 allele. Because this allele is more common among Southeast…
  • « Previous Page
  • 1
  • …
  • 71
  • 72
  • 73
  • 74
  • 75
  • …
  • 2607
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology